Medical Background Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1 analogue) originally developed for type 2 diabetes management
I began doing Weight Watchers on and off, and started running too
In practice, some prescribers may use semaglutide off-label in selected patients who have insulin resistance, excess weight, or features of metabolic syndrome, but this should only happen under medical supervision
Patients approved for the PAP receive free Ozempic or Rybelsus from Novo Nordisk without registration charges or monthly fees
Novo (NVO) faces near-term pricing pressure and mix risk on its high-margin GLP-1 franchise
"It's a marketing technique by the companies." "If you study it for diabetes, even if it affects weight loss, they can't market it for weight loss because it doesn't have the indication for weight loss